Much Ado About Nothing Much With Atara's MS Hopeful

Interim Analysis On ATA188 Reveals Little

 
• By Kevin Grogan
  
2023
Atara builds towards a successful 2023 when its multiple sclerosis data will read out • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D